FSD Pharma (also known by its subsidiary’s name, FV Pharma) is officially gone from the cannabis sector.

FSD is liquidating all of FV Pharma’s assets, and has probably lost a potential buyer in Rosy Mondin of World Class ($PUMP), since she’s just bought her own bouncing baby Pharmaceutical company. Maybe she’ll purchase the assets/building, and consolidate, maybe she’ll just walk. It could come out in a couple of different ways depending on what assets all of these outfits have. Either or, another ‘cannabis’ company in FSD has left the sector for greener COVID pastures.

Long time readers will recall how FSD had run up on the contractual rocks with Auxly, who quickly dashed into the waiting pharmaceutical arms of an outfit called ‘KGK’. I was reminded of how Rosy had sublet space in FSD’s facilities shortly after the breakup with Auxly – to build out an extraction facility for $PUMP.

I don’t have too good of a sightline on many of the ‘Pharma’ and ‘Pharma-lite’ companies and claims of IP. Specifically: Dosecann; $PILL; HydRx; $OILS; Ginko; $WLLW; $TPB; etc etc. Cyto and I are going to head down this road though, and see if we can’t surface some key differentiators (if they exist). While he’s been looking from the patent side, we’ll see if we can’t find something useful as well in their approaches or modalities.

They’ve had enough time in build to now be demonstrating some hard lines around their business models.

The FSD pivot is amazing coincidence in that the timing couldn’t have been better for Rosy to find another shop to set up shop in. One is led to wonder whether her buy of HydRx came from within, or whether the choice was forced by FSD’s exit.

The preceding is the opinion of the author, and is in no way intended to be a recommendation to buy or sell any security or derivative. The author holds position in $PUMP.